DR info

臨床試験数 : 149 / 薬物数 : 202 - (DrugBank : 78) / 標的遺伝子数 : 66 - 標的パスウェイ数 : 169

薬物ごとの開発者（Primary Sponsor）、臨床試験情報（抜粋）です。

13NH3 PET/CT scan
   Mayo Clinic
      2018   Phase 4   NCT03549598   United States;
18F-FDG
   British Columbia Cancer Agency
      2012   -   NCT01764191   Canada;
   St. Olavs Hospital
      2018   -   NCT03561025   Norway;
   Tokushima University Hospital
      2010   -   JPRN-UMIN000004267   Japan;
   University Health Network, Toronto
      2016   -   NCT03356756   Canada;
   University of Edinburgh
      2018   -   NCT03705884   United Kingdom;
18F-FSPG
   Stanford University
      2017   Phase 2   NCT03103490   United States;
18F-fluorodeoxyglucose
   Turku PET Centre
      2016   -   EUCTR2015-001815-11-FI   Finland;
18FDG PET/CT scan
   Mayo Clinic
      2018   Phase 4   NCT03549598   United States;
68Ga-DOTANOC
   Turku PET Centre
      2016   -   EUCTR2015-001815-11-FI   Finland;
68Ga-DOTATATE PET/CT
   Mayo Clinic
      2018   Phase 4   NCT03549598   United States;
99m technetium infliximab
   Sint Antonius Hospital
      2011   -   EUCTR2011-003630-13-NL   Netherlands;
99mTc-Infliximab
   Sint Antonius Hospital
      2011   -   EUCTR2011-003630-13-NL   Netherlands;
ABPC
   Respiratory medicine, Juntendo university.
      2012   -   JPRN-UMIN000008813   Japan;
ACT-293987 / JNJ-67896049
   ACTELION PHARMACEUTICALS LTD
      2019   Phase 2;Phase 3   EUCTR2018-004887-74-IT   Belgium;Brazil;Canada;Czechia;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
   Actelion Pharmaceuticals Ltd
      2020   Phase 2   EUCTR2018-004887-74-DE   Belgium;Brazil;Canada;Czech Republic;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
      2019   Phase 2;Phase 3   EUCTR2018-004887-74-PL   Argentina;Belgium;Brazil;Canada;China;Czech Republic;Denmark;France;Germany;Hungary;India;Italy;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
      2019   Phase 2;Phase 3   EUCTR2018-004887-74-HU   Argentina;Belgium;Brazil;Canada;China;Czech Republic;Denmark;France;Germany;Hungary;India;Italy;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
      2019   Phase 2;Phase 3   EUCTR2018-004887-74-ES   Argentina;Belgium;Brazil;Canada;China;Czech Republic;Denmark;France;Germany;Hungary;India;Italy;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-004887-74-NL   Belgium;Brazil;Canada;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-004887-74-GB   Belgium;Brazil;Canada;Czechia;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
ACTHAR Gel (adrenocorticotropic hormone)
   Albany Medical College
      2015   Phase 2/Phase 3   NCT02155803   United States;
ACTHAR Gel 40 units twice weekly
   Albany Medical College
      2015   Phase 2/Phase 3   NCT02348905   United States;
ACTHAR Gel 80 units twice weekly.
   Albany Medical College
      2015   Phase 2/Phase 3   NCT02348905   United States;
ACZ885
   Novartis Pharma Services AG
      2016   Phase 2   EUCTR2016-001255-49-NL   Germany;Netherlands;United States;
      2016   Phase 2   EUCTR2016-001255-49-DE   Germany;Netherlands;United States;
      2015   -   EUCTR2013-005333-21-NL   Netherlands;United States;
   Novartis Pharmaceuticals
      2016   Phase 2   NCT02888080   Germany;Netherlands;United States;
AMPC
   Respiratory medicine, Juntendo university.
      2012   -   JPRN-UMIN000008813   Japan;
ARA 290
   Araim Pharmaceuticals
      2013   -   EUCTR2013-003016-45-NL   Netherlands;United States;
   Araim Pharmaceuticals, Inc.
      2014   Phase 2   NCT02039687   Netherlands;United States;
ATYR1923
   aTyr Pharma, Inc.
      2019   Phase 2   EUCTR2018-004244-33-DE   Germany;United States;
      2019   Phase 1/Phase 2   NCT03824392   United States;
Abatacept
   University of Chicago
      2008   Phase 2   NCT00739960   United States;
Acthar Gel
   Mallinckrodt
      2018   Phase 4   NCT03320070   United States;
Adalimumab
   Pariser, Robert J., M.D.
      2006   Phase 2   NCT00274352   United States;
   University of Chicago
      2006   Phase 2   NCT00311246   United States;
   Wake Forest University
      2007   Phase 2   NCT00690911   United States;
All subjects will receive maraviroc 300mg orally twice a day for 6 weeks
   Kevin F. Gibson
      2014   -   NCT02134717   United States;
Allogeneic stem cell transplantation
   Northwestern University
      2003   Phase 1/Phase 2   NCT00282438   United States;
Ambrisentan
   Medical University of South Carolina
      2008   Phase 2/Phase 3   NCT00851929   United States;
Anakinra
   Virginia Commonwealth University
      2020   Phase 2   NCT04017936   United States;
Analysis of gamma globulin
   Rennes University Hospital
      2017   -   NCT03259282   France;
Antibiotic Regimen
   Vanderbilt University
      2010   Phase 1/Phase 2   NCT01074554   United States;
Antituberculous therapy along with steroids
   Postgraduate Institute of Medical Education and Research
      2009   -   NCT01245036   India;
Armodafinil
   University of Cincinnati
      2007   Phase 2/Phase 3   NCT00555347   United States;
Atorvastatin
   National Heart, Lung, and Blood Institute (NHLBI)
      2006   Phase 2   NCT00279708   United States;
Autologous hematopoietic stem cell transplantation
   Northwestern University
      2003   Phase 1/Phase 2   NCT00282438   United States;
Azithromycin
   Vanderbilt University
      2014   Phase 2   NCT02024555   United States;
Azithromycin 250Mg Capsule
   Hull University Teaching Hospitals NHS Trust
      2019   Phase 2   NCT04020380   United Kingdom;
Azithromycin monohydrate
   Hull & East Yorkshire Hospitals NHS trust
      2019   Phase 2   EUCTR2019-000580-24-GB   United Kingdom;
Bardoxolone methyl
   Reata Pharmaceuticals, Inc.
      2014   Phase 2   NCT02036970   Germany;Spain;United Kingdom;United States;
Blood pressure
   Daniel Franzen
      2015   Phase 4   NCT02246023   Switzerland;
Blood sample
   Vastra Gotaland Region
      2020   -   NCT04206163   Sweden;
Bosentan
   Daniel Doberer
      2009   Phase 2   NCT00926627   Austria;
   Medical University of Vienna, Department of Clinical Pharmacology
      2008   -   EUCTR2007-005117-18-AT   Austria;
   University of Cincinnati
      2008   Phase 2/Phase 3   NCT00581607   United States;
Bosentan monohydrate
   St Georges Hospital
      2007   Phase 4   EUCTR2006-005361-19-GB   United Kingdom;
Bronchoalveolar lavage (BAL)
   Medical University of Warsaw
      2013   -   NCT01836822   Poland;
Bronchoscopy with bronchoalveolar lavage
   Kevin F. Gibson
      2014   -   NCT02134717   United States;
C11-methionine
   Turku PET Centre
      2016   -   EUCTR2015-001815-11-FI   Finland;
CC-100004
   University of Cincinnati
      2008   Phase 2/Phase 3   NCT00794274   United States;
CC-220 0.3 mg Daily
   Celgene
      2014   Phase 2   NCT02192489   -
CC-220 0.6mg Daily
   Celgene
      2014   Phase 2   NCT02192489   -
CMK389
   Novartis Pharma AG
      2020   Phase 2   EUCTR2018-000381-11-PL   Czechia;Denmark;Germany;Poland;United Kingdom;United States;
      2020   Phase 2   EUCTR2018-000381-11-GB   Czech Republic;Denmark;Germany;Poland;United Kingdom;United States;
      2020   Phase 2   EUCTR2018-000381-11-DK   Czechia;Denmark;Germany;Poland;United Kingdom;United States;
      2020   Phase 2   EUCTR2018-000381-11-DE   Czechia;Denmark;Germany;Poland;United Kingdom;United States;
   Novartis Pharmaceuticals
      2020   Phase 2   NCT04064242   Czechia;Denmark;Germany;Poland;United Kingdom;United States;
CNTO 148
   Centocor BV
      2009   Phase 2   EUCTR2009-010714-30-FR   Belgium;Denmark;France;Germany;Italy;Netherlands;United Kingdom;
      2009   -   EUCTR2009-010714-30-NL   Belgium;Denmark;France;Germany;Italy;Netherlands;United Kingdom;
   Janssen Biologics B.V.
      2009   Phase 2   EUCTR2009-010714-30-GB   Belgium;Denmark;France;Germany;Italy;Netherlands;United Kingdom;
      2009   -   EUCTR2009-010714-30-DK   Belgium;Denmark;France;Germany;Italy;Netherlands;Romania;United Kingdom;United States;
      2009   -   EUCTR2009-010714-30-DE   Belgium;Denmark;France;Germany;Italy;Netherlands;United Kingdom;
      2009   -   EUCTR2009-010714-30-BE   Belgium;Denmark;France;Germany;Italy;Netherlands;Norway;United Kingdom;United States;
CNTO1275
   CENTOCOR
      2010   -   EUCTR2009-010714-30-IT   Belgium;Denmark;France;Germany;Italy;Netherlands;United Kingdom;
   Centocor BV
      2009   Phase 2   EUCTR2009-010714-30-FR   Belgium;Denmark;France;Germany;Italy;Netherlands;United Kingdom;
      2009   -   EUCTR2009-010714-30-NL   Belgium;Denmark;France;Germany;Italy;Netherlands;United Kingdom;
   Janssen Biologics B.V.
      2009   Phase 2   EUCTR2009-010714-30-GB   Belgium;Denmark;France;Germany;Italy;Netherlands;United Kingdom;
      2009   -   EUCTR2009-010714-30-DK   Belgium;Denmark;France;Germany;Italy;Netherlands;Romania;United Kingdom;United States;
      2009   -   EUCTR2009-010714-30-DE   Belgium;Denmark;France;Germany;Italy;Netherlands;United Kingdom;
      2009   -   EUCTR2009-010714-30-BE   Belgium;Denmark;France;Germany;Italy;Netherlands;Norway;United Kingdom;United States;
CNTO148
   CENTOCOR
      2010   -   EUCTR2009-010714-30-IT   Belgium;Denmark;France;Germany;Italy;Netherlands;United Kingdom;
Calcium Citrate with Vitamin D2
   University of Texas Southwestern Medical Center
      2010   Phase 4   NCT03621553   United States;
Canakinumab
   Novartis Pharma Services AG
      2016   Phase 2   EUCTR2016-001255-49-NL   Germany;Netherlands;United States;
      2016   Phase 2   EUCTR2016-001255-49-DE   Germany;Netherlands;United States;
      2015   -   EUCTR2013-005333-21-NL   Netherlands;United States;
Ciclesonide
   Department of Respirology, Graduate School of Medicine, Chiba University, Chiba, Japan
      2014   -   JPRN-UMIN000013831   Japan;
Clarithromycin
   National cerebral and cardiovascular center
      2017   -   JPRN-UMIN000025936   Japan;
   Takase Hiroshi
      2017   Phase 1-2   JPRN-jRCTs031180301   Japan;
Corticosteroid
   Oregon Health and Science University
      2019   Phase 1   NCT03793439   United States;
Cu-64 DOTATATE
   Rigshospitalet, Denmark
      2016   -   NCT02812849   Denmark;
Cyclophosphamide
   National Heart, Lung, and Blood Institute (NHLBI)
      1978   Phase 2   NCT00000596   -
D-methylphenidate
   University of Cincinnati
      2006   Phase 4   NCT00361387   United States;
DELTACORTENE*10CPR
   UNIVERSITA' DEGLI STUDI DI MILANO-BICOCCA
      2008   -   EUCTR2008-001340-39-IT   Italy;
DOTANOC
   St. Antonius Hospital
      2016   Phase 2   EUCTR2016-002160-14-NL   Netherlands;
   Turku University Hospital
      2016   Phase 2/Phase 3   NCT02824419   Finland;
Dapsone
   National Heart, Lung, and Blood Institute (NHLBI)
      1978   Phase 2   NCT00000596   -
Dexamethasone
   St. Antonius Hospital
      2013   Phase 3   NCT01920919   Netherlands;
Dexamethasone 0,
Doxycycline
   National cerebral and cardiovascular center
      2017   -   JPRN-UMIN000025936   Japan;
EBB + TBLB + BAL
   Leiden University Medical Center
      2009   Phase 3   NCT00872612   Belgium;Denmark;Germany;Netherlands;Poland;United Kingdom;
EBUS guided transbronchial forceps biopsy (EBUS-TBFB)
   Medical University of Warsaw
      2013   -   NCT01836822   Poland;
EBUS guided transbronchial needle aspiration (EBUS-TBNA)
   Medical University of Warsaw
      2013   -   NCT01836822   Poland;
EUS-FNA/EBUS-TBNA + BAL
   Leiden University Medical Center
      2009   Phase 3   NCT00872612   Belgium;Denmark;Germany;Netherlands;Poland;United Kingdom;
Endobronchial forceps biopsy
   Medical University of Warsaw
      2013   -   NCT01836822   Poland;
Ergocalciferol
   University of Texas Southwestern Medical Center
      2010   Phase 4   NCT03621553   United States;
Ethambutol
   Vanderbilt University
      2014   Phase 2   NCT02024555   United States;
      2010   Phase 1   NCT01169038   United States;
FDG
   Turku PET Centre
      2016   -   EUCTR2015-001815-11-FI   Finland;
FLUORINE (18F) FLUDEOXYGLUCOSE
   Turku PET Centre
      2016   -   EUCTR2015-001815-11-FI   Finland;
Faecal microbiota transplantation
   Torkell Ellingsen
      2022   Phase 2   NCT04924270   -
Fermented oyster extract
   Pusan National University Yangsan Hospital
      2019   -   NCT04109911   Korea, Republic of;
Flexible bronchoscopy in moderate sedation
   Daniel Franzen
      2015   Phase 4   NCT02246023   Switzerland;
Fluorodeoxyglucose
   Yale University
      2017   Early Phase 1   NCT03048097   United States;
Folic acid
   Murohara Toyoaki
      2016   Phase 3   JPRN-jRCTs041180111   Japan;
   Toshiyuki Nagai
      2021   Phase 3   JPRN-jRCTs011210048   Canada;Japan;United Kingdom;United States;
Ga-68-DOTA-NOC
   St. Antonius Hospital
      2016   Phase 2   EUCTR2016-002160-14-NL   Netherlands;
Gallium-68 DOTATATE
   Marcelo F. Di Carli, MD, FACC
      2015   -   NCT02546388   United States;
   University of Pennsylvania
      2018   -   NCT03746847   United States;
Gallium-68-DOTA-N-Octreotide
   St. Antonius Hospital
      2016   Phase 2   EUCTR2016-002160-14-NL   Netherlands;
Glucocorticoid (prednisone or prednisolone)
   Celgene
      2017   -   NCT03324503   Netherlands;United Kingdom;United States;
Gold
   Department of Respiratory Medicine, Shanghai Pulmonary Hospital, Tongji University School of Medicine
      2015   -   ChiCTR-DCD-15007110   China;
   Shanghai Pulmonary Hospital Tongji University, School of Medicine
      2020   Phase 0   ChiCTR2000036043   China;
Golimumab
   CENTOCOR
      2010   -   EUCTR2009-010714-30-IT   Belgium;Denmark;France;Germany;Italy;Netherlands;United Kingdom;
   Centocor, Inc.
      2009   Phase 2   NCT00955279   Belgium;Denmark;France;Germany;Netherlands;Norway;Romania;Sweden;United Kingdom;United States;
Golimumab Liquid in prefilled syringe
   Centocor BV
      2009   Phase 2   EUCTR2009-010714-30-FR   Belgium;Denmark;France;Germany;Italy;Netherlands;United Kingdom;
      2009   -   EUCTR2009-010714-30-NL   Belgium;Denmark;France;Germany;Italy;Netherlands;United Kingdom;
   Janssen Biologics B.V.
      2009   Phase 2   EUCTR2009-010714-30-GB   Belgium;Denmark;France;Germany;Italy;Netherlands;United Kingdom;
      2009   -   EUCTR2009-010714-30-DK   Belgium;Denmark;France;Germany;Italy;Netherlands;Romania;United Kingdom;United States;
      2009   -   EUCTR2009-010714-30-DE   Belgium;Denmark;France;Germany;Italy;Netherlands;United Kingdom;
      2009   -   EUCTR2009-010714-30-BE   Belgium;Denmark;France;Germany;Italy;Netherlands;Norway;United Kingdom;United States;
H.P. Acthar Gel
   University of Maryland, Baltimore
      2016   Phase 4   NCT02298491   United States;
Habitrol
   Ohio State University
      2015   Phase 1/Phase 2   NCT02265874   United States;
Heparin
   Tokushima University Hospital
      2010   -   JPRN-UMIN000004267   Japan;
Human anti TNF-alpha monoclonal antibody
   Centocor BV
      2009   Phase 2   EUCTR2009-010714-30-FR   Belgium;Denmark;France;Germany;Italy;Netherlands;United Kingdom;
      2009   -   EUCTR2009-010714-30-NL   Belgium;Denmark;France;Germany;Italy;Netherlands;United Kingdom;
   Janssen Biologics B.V.
      2009   Phase 2   EUCTR2009-010714-30-GB   Belgium;Denmark;France;Germany;Italy;Netherlands;United Kingdom;
      2009   -   EUCTR2009-010714-30-DK   Belgium;Denmark;France;Germany;Italy;Netherlands;Romania;United Kingdom;United States;
      2009   -   EUCTR2009-010714-30-DE   Belgium;Denmark;France;Germany;Italy;Netherlands;United Kingdom;
      2009   -   EUCTR2009-010714-30-BE   Belgium;Denmark;France;Germany;Italy;Netherlands;Norway;United Kingdom;United States;
Human anti-IL 12/23 monoclonal antibody
   Centocor BV
      2009   Phase 2   EUCTR2009-010714-30-FR   Belgium;Denmark;France;Germany;Italy;Netherlands;United Kingdom;
      2009   -   EUCTR2009-010714-30-NL   Belgium;Denmark;France;Germany;Italy;Netherlands;United Kingdom;
   Janssen Biologics B.V.
      2009   Phase 2   EUCTR2009-010714-30-GB   Belgium;Denmark;France;Germany;Italy;Netherlands;United Kingdom;
      2009   -   EUCTR2009-010714-30-DK   Belgium;Denmark;France;Germany;Italy;Netherlands;Romania;United Kingdom;United States;
      2009   -   EUCTR2009-010714-30-DE   Belgium;Denmark;France;Germany;Italy;Netherlands;United Kingdom;
      2009   -   EUCTR2009-010714-30-BE   Belgium;Denmark;France;Germany;Italy;Netherlands;Norway;United Kingdom;United States;
Humira
   Rigshospitalet
      2006   Phase 2   EUCTR2006-001816-56-DK   Denmark;
   Wright State University
      2009   Phase 2   NCT00731757   United States;
Hydroxychloroquine
   UNIVERSITA' DEGLI STUDI DI MILANO-BICOCCA
      2008   -   EUCTR2008-001340-39-IT   Italy;
Hydroxychloroquine + Prednisone
   University of Milano Bicocca
      2009   Phase 3   NCT02200146   Italy;
Hydroxychloroquine + low-dose prednisone
   Assistance Publique - Hôpitaux de Paris
      2022   Phase 3   NCT05247554   -
IMod.Fc, H-Fcv3-N4
   aTyr Pharma, Inc.
      2019   Phase 2   EUCTR2018-004244-33-DE   Germany;United States;
Iloprost
   University of Cincinnati
      2006   Phase 4   NCT00403650   United States;
Indium-111 Pentreotide
   Marcelo F. Di Carli, MD, FACC
      2015   -   NCT02546388   United States;
Infliximab
   Assistance Publique - Hôpitaux de Paris
      2019   Phase 3   NCT03704610   France;
   Centocor, Inc.
      2003   Phase 3   NCT00073437   Austria;Belgium;France;Germany;Italy;Netherlands;Sweden;Switzerland;United Kingdom;United States;
Influenza Vaccine
   Shahid Beheshti Medical University
      2008   -   NCT00828828   Iran, Islamic Republic of;
Inhaled Treprostinil
   University of Florida
      2020   Phase 2   NCT03814317   United States;
L-METHIONINE ([11C]METHYL)
   Turku PET Centre
      2016   -   EUCTR2015-001815-11-FI   Finland;
Large bore (19G) histologic needle biopsy of the mediastinal lymph nodes
   Medical University of Warsaw
      2013   -   NCT01836822   Poland;
Levaquin
   Vanderbilt University
      2010   Phase 1   NCT01169038   United States;
Levofloxacin
   Vanderbilt University
      2014   Phase 2   NCT02024555   United States;
Low dose prednisolone
   Postgraduate Institute of Medical Education and Research
      2017   Phase 4   NCT03265405   India;
MTX
   Murohara Toyoaki
      2016   Phase 3   JPRN-jRCTs041180111   Japan;
Medium dose prednisolone
   Postgraduate Institute of Medical Education and Research
      2017   Phase 4   NCT03265405   India;
Methionine
   Turku University Hospital
      2016   Phase 2/Phase 3   NCT02824419   Finland;
Methotrexate
   Assistance Publique - Hôpitaux de Paris
      2009   Phase 4   NCT00918554   France;
   Erasmus Medical Center
      2020   Phase 4   NCT04314193   Netherlands;
   Ottawa Heart Institute Research Corporation
      2019   Phase 3   NCT03593759   Canada;Japan;United Kingdom;United States;
   The Department of Cardiology, Nagoya University Graduate School of Medicine
      2016   -   JPRN-UMIN000022996   Japan;
   Toshiyuki Nagai
      2021   Phase 3   JPRN-jRCTs011210048   Canada;Japan;United Kingdom;United States;
Methylphenidate (overencapsulated)
   University of East Anglia
      2016   -   NCT02643732   United Kingdom;
Methylphenidate 10mg tablets
   Norfolk and Norwich University Hospital
      2016   Phase 2   EUCTR2016-000342-60-GB   United Kingdom;
Methylprednisolone bolus IV 15 mg/kg/d for 3 days.
   Assistance Publique - Hôpitaux de Paris
      2012   -   NCT01652417   France;
Minomycin
   Takase Hiroshi
      2017   Phase 1-2   JPRN-jRCTs031180301   Japan;
Mycophenolate
   Medical University of South Carolina
      2003   Phase 3   NCT00262132   United States;
N-acetyl-cysteine
   National Jewish Health
      2011   -   NCT01587001   United States;
Nelutri™
   Pusan National University Yangsan Hospital
      2020   -   NCT04320121   Korea, Republic of;
Nested PCR for formalin-fixed tissues
   Pusan National University Hospital
      2015   -   NCT02497079   Korea, Republic of;
Nested PCR for fresh tissues
   Pusan National University Hospital
      2015   -   NCT02497079   Korea, Republic of;
Nicotine patch
   Elliott Crouser MD
      2008   Early Phase 1   NCT00701207   United States;
None
   Norfolk and Norwich University Hospital
      2016   Phase 2   EUCTR2016-000342-60-GB   United Kingdom;
Octreotide LAR / Sandostatin LAR (LAR=long acting release)
   Erasmus Medical Center
      2014   -   EUCTR2013-005376-17-NL   Netherlands;
Oxygen saturation
   Daniel Franzen
      2015   Phase 4   NCT02246023   Switzerland;
PD 0360324
   Pfizer
      2013   Phase 2   NCT01732211   United States;
PDA001 (cenplacel-L)
   Celularity Incorporated
      2011   Phase 1   NCT01440192   United States;
PLAQUENIL*25CPR RIV
   UNIVERSITA' DEGLI STUDI DI MILANO-BICOCCA
      2008   -   EUCTR2008-001340-39-IT   Italy;
Pentoxifylline
   National Heart, Lung, and Blood Institute (NHLBI)
      1999   Phase 2   NCT00001877   United States;
Pirfenidone
   University of Cincinnati
      2017   Phase 4   NCT03260556   United States;
Prednisolone
   Erasmus Medical Center
      2020   Phase 4   NCT04314193   Netherlands;
   National cerebral and cardiovascular center
      2017   -   JPRN-UMIN000025936   Japan;
   The First Affiliated Hospital, Guangzhou Medical University
      2012   -   ChiCTR-IOR-15005953   -
   University of Edinburgh
      2018   -   NCT03705884   United Kingdom;
Prednison
   Erasmus Medisch Centrum Dept. of Pulmonology
      2020   Phase 4   EUCTR2019-004148-31-NL   Netherlands;
Prednisone
   National Heart, Lung, and Blood Institute (NHLBI)
      1978   Phase 2   NCT00000596   -
   Ottawa Heart Institute Research Corporation
      2014   Phase 4   NCT01210677   Canada;
   Toshiyuki Nagai
      2021   Phase 3   JPRN-jRCTs011210048   Canada;Japan;United Kingdom;United States;
   UNIVERSITA' DEGLI STUDI DI MILANO-BICOCCA
      2008   -   EUCTR2008-001340-39-IT   Italy;
Prednisone or Prednisolone
   Ottawa Heart Institute Research Corporation
      2019   Phase 3   NCT03593759   Canada;Japan;United Kingdom;United States;
Propofol dosage
   Daniel Franzen
      2015   Phase 4   NCT02246023   Switzerland;
Quercetin
   Maastricht University Medical Center
      2006   -   NCT00402623   Netherlands;
RNA Sequencing
   Oregon Health and Science University
      2019   Phase 1   NCT03793439   United States;
Rapamune
   Medical University of Vienna
      2019   Phase 2   EUCTR2017-004930-27-AT   Austria;
Real-time PCR for fresh tissues
   Pusan National University Hospital
      2015   -   NCT02497079   Korea, Republic of;
Recovery time after bronchoscopy
   Daniel Franzen
      2015   Phase 4   NCT02246023   Switzerland;
Remicade
   St. Antonius Hospital
      2015   -   EUCTR2014-002224-26-NL   Netherlands;
Repository Corticotropin Injection
   The Cleveland Clinic
      2019   Phase 4   NCT02920710   United States;
Repository Corticotropin Injection -Treatment Extension
   The Cleveland Clinic
      2016   -   NCT02725177   United States;
Rifampin
   Vanderbilt University
      2014   Phase 2   NCT02024555   United States;
Rifampin and azithromycin.
   Vanderbilt University
      2010   Phase 1   NCT01169038   United States;
Riociguat
   University of Cincinnati
      2015   Phase 4   NCT02625558   United States;
Rituximab
   University of Cincinnati
      2009   Phase 2   NCT00855205   United States;
Roflumilast
   University of Cincinnati
      2013   Phase 4   NCT01830959   United States;
Rubidium
   Assistance Publique - Hôpitaux de Paris
      2012   -   NCT01648933   France;
   Yale University
      2017   Early Phase 1   NCT03048097   United States;
Sarilumab 200 MG/1.14 ML Subcutaneous Solution [KEVZARA]_#1
   Stanford University
      2019   Phase 2   NCT04008069   United States;
Schisandra chinensis extract
   Pusan National University Yangsan Hospital
      2017   -   NCT03402308   Korea, Republic of;
Seasonal influenza vaccine available for the 2012-2013 vaccine campaign
   Assistance Publique - Hôpitaux de Paris
      2012   Phase 3   NCT01687517   France;
Selexipag
   ACTELION PHARMACEUTICALS LTD
      2019   Phase 2;Phase 3   EUCTR2018-004887-74-IT   Belgium;Brazil;Canada;Czechia;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
   Actelion
      2021   Phase 2   NCT03942211   Belgium;Brazil;Canada;Czechia;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States;
Sirolimus Ointment
   Medical University of Vienna
      2019   Phase 2   EUCTR2017-004930-27-AT   Austria;
Skin biopsy
   Kevin F. Gibson
      2014   -   NCT02134717   United States;
Tadalafil
   University of North Carolina, Chapel Hill
      2011   Phase 2/Phase 3   NCT01324999   United States;
Tofacitinib 5 mg twice daily
   Yale University
      2019   Phase 1   NCT03910543   United States;
Tofacitinib 5mg Oral Tablet [Xeljanz] 16 week trial
   Oregon Health and Science University
      2019   Phase 1   NCT03793439   United States;
Tofacitinib 5mg [Xeljanz] 1 year open-label extension
   Oregon Health and Science University
      2019   Phase 1   NCT03793439   United States;
Tracleer
   Medical University of Vienna, Department of Clinical Pharmacology
      2008   -   EUCTR2007-005117-18-AT   Austria;
   St Georges Hospital
      2007   Phase 4   EUCTR2006-005361-19-GB   United Kingdom;
Tranilast
   The First Affiliated Hospital with Nanjing Medical University
      2018   Early Phase 1   NCT03528070   -
Uptravi
   ACTELION PHARMACEUTICALS LTD
      2019   Phase 2;Phase 3   EUCTR2018-004887-74-IT   Belgium;Brazil;Canada;Czechia;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
   Actelion Pharmaceuticals Ltd
      2020   Phase 2   EUCTR2018-004887-74-DE   Belgium;Brazil;Canada;Czech Republic;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
      2019   Phase 2;Phase 3   EUCTR2018-004887-74-PL   Argentina;Belgium;Brazil;Canada;China;Czech Republic;Denmark;France;Germany;Hungary;India;Italy;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
      2019   Phase 2;Phase 3   EUCTR2018-004887-74-HU   Argentina;Belgium;Brazil;Canada;China;Czech Republic;Denmark;France;Germany;Hungary;India;Italy;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
      2019   Phase 2;Phase 3   EUCTR2018-004887-74-ES   Argentina;Belgium;Brazil;Canada;China;Czech Republic;Denmark;France;Germany;Hungary;India;Italy;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-004887-74-NL   Belgium;Brazil;Canada;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-004887-74-GB   Belgium;Brazil;Canada;Czechia;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
Ustekinumab
   CENTOCOR
      2010   -   EUCTR2009-010714-30-IT   Belgium;Denmark;France;Germany;Italy;Netherlands;United Kingdom;
   Centocor, Inc.
      2009   Phase 2   NCT00955279   Belgium;Denmark;France;Germany;Netherlands;Norway;Romania;Sweden;United Kingdom;United States;
Ustekinumab liquid in prefilled syringe
   Centocor BV
      2009   Phase 2   EUCTR2009-010714-30-FR   Belgium;Denmark;France;Germany;Italy;Netherlands;United Kingdom;
      2009   -   EUCTR2009-010714-30-NL   Belgium;Denmark;France;Germany;Italy;Netherlands;United Kingdom;
   Janssen Biologics B.V.
      2009   Phase 2   EUCTR2009-010714-30-GB   Belgium;Denmark;France;Germany;Italy;Netherlands;United Kingdom;
      2009   -   EUCTR2009-010714-30-DK   Belgium;Denmark;France;Germany;Italy;Netherlands;Romania;United Kingdom;United States;
      2009   -   EUCTR2009-010714-30-DE   Belgium;Denmark;France;Germany;Italy;Netherlands;United Kingdom;
      2009   -   EUCTR2009-010714-30-BE   Belgium;Denmark;France;Germany;Italy;Netherlands;Norway;United Kingdom;United States;
Venipunctures
   Kevin F. Gibson
      2014   -   NCT02134717   United States;
Water
   Hokkaido University Graduate School of Medicine
      2010   -   JPRN-UMIN000006533   Japan;
[64]Cu Macrin
   Ralph Weissleder, MD
      2021   Phase 1   NCT04843891   United States;